Xenetic Biosciences (XBIO)
(Delayed Data from NSDQ)
$3.90 USD
-0.15 (-3.62%)
Updated May 10, 2024 03:49 PM ET
After-Market: $3.85 -0.05 (-1.17%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Xenetic Biosciences, Inc. [XBIO]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
2023 Results; 2024 Brings Prospects of Phase 1 Pancreatic Carcinoma Study; Financial Strains Persist
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
3Q23 Results; Phase 1 Pancreatic Carcinoma Study Slated For 2024; Significant Financial Overhang Remains
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Waiting For Line of Sight to Clinic; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
New Collaboration Supports Advancement of DNase-Based Platform Toward the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
2022 Results; DNase-Based Platform Aims to Differentiate With Approaching Phase 1 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
3Q22 Results; DNAse-Based Oncology Platform Getting Ready to Initiate Clinical Journey
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
2Q22 Results; With Recent Shift In Focus to DNAse-Based Oncology Platform, All Eyes on Starting Phase 1 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
1Q22 Results; DNAse-Based Oncology Platform Marches Towards Clinical Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Focus Builds with Pipeline Addition; Price Target Adjusted to $4
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Intriguing Addition to Pipeline; NETs Being Targeted in Oncology; Doors Can Open to Further Immune Killing of Tumors
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
2Q21 Results; Progress Continues Toward IND-Enabling Studies for XCART
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
1Q21 Results; Continuing to Build the XCART Profile
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
2020 Results; Key Focus on Moving XCART to the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Positive Partner Headline Using PolyXen; Focus on XCART Initial Clinical Steps in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Expecting Meaningful Visibility Boost from XCART Program in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
3Q20 Results; Progress Continues Towards XCART Clinical Development
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
2Q20 Results; Key Collaborations Are Set to Push XCART Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Xenetic Delivers Key Collaboration to Move XCART Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Xenetic Biosciences, Inc.
Industry: Medical - Drugs
Cozying up to Scripps to Push XCART Closer to the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J